Drug Research
Tonix advances development of TNX-801 to prevent mpox infection
Tonix Pharmaceuticals Holding Corp., a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, has reiterated its commitment to advance development of its live attenuated virus vaccine, TNX-801 , for preventing mpox and other infectious diseases....
Drug Research
Nuntius Therapeutics Announces Collaboration with Taiho Pharmaceutical to Develop Next-Generation mRNA Therapies
Nuntius Therapeutics, a biotech company developing transformative mRNA therapies through their advanced delivery technology announced that they have entered into a collaboration agreement with Taiho Pharmaceutical Co., Ltd. (“Taiho”), a leading company in Japan for developing innovative medicines for...
Drug Research
Nanoform and Takeda to Collaborate on Plasma-Derived Therapy Formulation
Nanoform Finland Plc , the medicine performance-enhancing company announced that it is to enter into a pre-clinical development agreement with the Plasma-derived Therapies Business Unit of Takeda Pharmaceuticals, Inc., the R&D-driven biopharmaceutical company headquartered in Japan, to develop innovative...
Drug Research
Baxter Announces Definitive Agreement to Divest Its Vantive Kidney Care Segment to Carlyle for $3.8 Billion
Baxter International Inc., a global medtech leader, and funds managed by global investment firm Carlyle announced that they have signed a definitive agreement under which Carlyle is to acquire Baxter's Kidney Care segment, to be named Vantive, for $3.8...
Drug Research
Daiichi And MSD Broaden DXd ADC Collaboration Worldwide
Daiichi Sankyo and MSD have widened their partnership to create and market three DXd-based antibody-drug conjugates (ADCs) all over the world.
DXd is the name of Daiichi Sankyo's unique ADC technology platform. MK-6070, MSD's delta-like ligand 3 (DLL3) targeting T-cell...
Drug Research
With a $400M Deal: Ideaya Targets Biocytogens BsADC Program
For an option on Biocytogen Pharmaceuticals' possible first-in-class B7H3/PTK7 BsADC program, Ideaya Biosciences is paying more than $400 million. The goal of antibody drug conjugates (ADCs) is to give highly focused therapy by combining the cytotoxic medicines with the...
Drug Research
Eli Lilly Invests In Actinium-225 To Support Radiopharma
The largest pharmaceutical company in the world based on market value, Eli Lilly, is getting into the nuclear isotope manufacturing industry as cancer medicine manufacturers want to ensure a supply of radioactive elements essential to the developing area of...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
